Introducing our patented gene therapy drug delivery platform! Pioneering a new era in managing depression, alcohol use disorder, and other neurological disorders.Leading the Charge in Behavioral Health: Pathways Neuro PharmaAt Pathways Neuro Pharma, we are developing groundbreaking treatments for Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD). By upregulating serotonin and dopamine receptors with endogenous G protein-targeted therapies and advancing innovative gene therapies, we promise real change.Our AAV6.2FF gene therapy platform not only enhances transgene expression in the brain but does so for up to 15 months with a single treatment, ensuring sustained therapeutic effects and improved patient compliance. This extended duration surpasses approved therapies, reducing the need for frequent dosing and improving overall quality of life for patients.Consider these staggering statistics: in the US alone, 29.5 million individuals aged 12 and older struggled with AUD in 2022, and 21 million adults experienced a major depressive episode in 2021.Our mission: revolutionize behavioral health with the AAV6.2FF Drug Delivery Platform, aiming to mitigate the side effects of serotonin agonist drugs and control long-term behaviors associated with depression.We are committed to transforming behavioral health care by providing safer, more effective, and long-lasting treatments for depression, alcoholism, and other neurological disorders.

Development of Transdermal and Topical Patch Drug Delivery Systems. Transdermal and Topical Patch Research and Manufacturing.